A Phase IIIb Randomised, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm Study to Evaluate the Effect of Elafibranor 80 mg on Normalisation of Alkaline Phosphatase in Adult Participants With Primary Biliary Cholangitis (PBC) and Inadequate Response or Intolerance to Ursodeoxycholic Acid
Latest Information Update: 09 May 2025
At a glance
- Drugs Elafibranor (Primary)
- Indications Primary biliary cirrhosis
- Focus Registrational; Therapeutic Use
- Acronyms ELSPIRE
- Sponsors Ipsen
Most Recent Events
- 01 May 2025 Status changed from recruiting to active, no longer recruiting.
- 02 Aug 2024 Planned End Date changed from 21 Dec 2026 to 31 Oct 2026.
- 02 Aug 2024 Planned primary completion date changed from 22 Jun 2026 to 31 Oct 2026.